EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 3.0

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

B Uz, O Bektas, E Eliacık, H Goker, Y Erbilgin, M Sayitoglu, N Sayinalp, S Aksu, Y Buyukasik, O Ozcebe, I C Haznedaroglu

Case Reports in Hematology · 2011

DOI: 10.1155/2011/263725 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Hematology, 2011. Verfasst von B Uz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hacettepe University Medical School, 06100 Ankara, Turkey. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the administration of bosutinib, imatinib mesylate, nilotinib, dasatinib, interferon alpha 2a, cytotoxic chemotherapy, and allogeneic hematopoietic stem cell transplantation. The striking point of this case story is that no Abl kinase domain mutation against TKIs has been detected during this very complicated disease course of CML. Meanwhile, challenging cases will always be present despite the hope and progress in CML in the TKI era.

Autor:innen und Institutionen

  • Department of Hematology, Hacettepe University Medical School, 06100 Ankara, Turkey.

Zitieren

APA

Uz, B., Bektas, O., Eliacık, E., Goker, H., Erbilgin, Y., Sayitoglu, M., Sayinalp, N., Aksu, S., Buyukasik, Y., Ozcebe, O., & Haznedaroglu, I. C. (2011). Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation. Case Reports in Hematology. https://doi.org/10.1155/2011/263725

Vancouver

Uz B, Bektas O, Eliacık E, Goker H, Erbilgin Y, Sayitoglu M, et al. Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation. Case Reports in Hematology. 2011. doi:10.1155/2011/263725

BibTeX
@article{Uz2011,
  author = {Uz, B and Bektas, O and Eliacık, E and Goker, H and Erbilgin, Y and Sayitoglu, M and Sayinalp, N and Aksu, S and Buyukasik, Y and Ozcebe, O and Haznedaroglu, I C},
  title = {Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation},
  journal = {Case Reports in Hematology},
  year = {2011},
  doi = {10.1155/2011/263725}
}
Kostenlos starten →